Beijing Tsinghua Changgung Hospital
Beijing, 102218, China
NCT Number: NCT06621485
Using the multicenter data, we developed and validated an individualized online calculator to predict early mortality after liver resection for hepatocellular carcinoma. The user-friendly tool with 6 preoperative predictors demonstrated excellent accuracy. The freely available calculator may help identify high-risk patients and reduce futile liver resection for hepatocellular carcinoma.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Beijing, 102218, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adults (age ≥18 years) who underwent curative-intent hepatectomy for newly diagnosed HCC.
HCC diagnosis was confirmed histopathologically.
Exclusion criteria
Patients undergoing emergency hepatectomy for tumor rupture, as well as individuals with recurrent HCC, and those with missing survival data or less than 90 days of follow-up were excluded.
Time frame: The period starts from the day of the hepatectomy surgery and extends up to the 90th day post-surgery.
90-day mortality after hepatectomy for HCC
Beijing Tsinghua Chang Gung Hospital
Other
Multi-institutional Development and Validation of an Individualized Online Calculator for Early Mortality Risk After Hepatectomy Among Patients With Hepatocellular Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04892810
Adenocarcinoma, Carcinoma
Grenoble, France
View Trial DetailsNCT04930315
Adenocarcinoma, Carcinoma
Hangzhou, Zhejiang, China
View Trial DetailsNCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial Details